Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | GALR3 | O60755 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20190329 | 0.87 | ALDH1A1 (0.52) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL2550445 | 0.86 | ALDH1A1 (0.52) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL1622071 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL19784557 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL19784711 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL5711986 | 0.80 | ALDH1A1 (0.48) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL21835889 | 0.79 | THRB (0.50) | ALDH1A1TSHRCA2HTTCA1 | |
| SCHEMBL10669272 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL47547 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL14079443 | 0.77 | ALDH1A1 (0.41) | ALDH1A1CHRM5CHRM1CHRM3PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081019-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2023217232-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217230-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-20230159477-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159477-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2023-05-25 | — | — | US | disclosed |
| WO-2022222856-A1 | BENZO-CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2022-10-27 | — | — | WO | disclosed |
| EP-4011871-A2 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | Geistlich Pharma AG (CH) | 2022-06-15 | — | — | EP | disclosed |
| EP-3233813-B1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2022-02-02 | — | — | EP | disclosed |
| US-20210163432-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | GEISTLICH PHARMA AG (CH) | 2021-06-03 | — | — | US | disclosed |
| US-10968190-B2 | Processes for preparing oxathiazin-like compounds | GEISTLICH PHARMA AG (CH) | 2021-04-06 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| EP-0906279-B1 | PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-6136844-A | ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISEASE | SYNTEX (U.S.A.) INC. (US) | 2000-10-24 | — | — | US | disclosed |
| US-6127402-A | AN INHIBITORS OF PROSTAGLANDIN G/H SYNTHASE AND ARE ANTI-INFLAMMATORY AND ANALGESIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-5952368-A | AN INHIBITORS OF PROSTAGLANDIN G/H SYNTHASE, ANTIINFLAMMATORY AND ANALGESIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0906279-A1 | NOVEL PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997046524-A1 | NOVEL PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | ALDH1A1 503/4885CHRM5 1397/4885CHRM1 802/4885 |
| US-20230159477-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | OXA1L, MAPT, OTC | ALDH1A1 3427/4885CHRM5 3316/4885CHRM1 3565/4885 |
| US-10968190-B2 | Processes for preparing oxathiazin-like compounds | DCXR, SORD, ADH1C | ALDH1A1 1291/4885CHRM5 2076/4885CHRM1 3252/4885 |
| US-20210163432-A1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | OXA1L, MAPT, OTC | ALDH1A1 3427/4885CHRM5 3316/4885CHRM1 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.